Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.

On-press developable, negative-working infrared radiation-sensitive lithographic printing plate precursors have an aluminum-containing substrate having at least inner and outer aluminum oxide layers. A hydrophilic layer is present on the outer aluminum oxide layer at 0.0002-0.1 g/m.sup.2 and contains a phosphorus-containing compound represented by Formula (I) at a coverage of 50-300 mg/m.sup.2. A hydrophilic polymer can also be present at a lower coverage than that of the phosphorus-containing compound. These precursors have an on-press developable, negative-working infrared radiation-sensitive imageable layer having at least a free radically polymerizable component; an initiator composition that provides free radicals upon exposure to imaging infrared radiation; an infrared radiation absorber having an anionic chromophore; and optionally a polymeric binder that is different from all other components. Such precursors can be imaged and on-press developed to provide lithographic printing plates, and they can be readily manufactured using a particular sequence of steps including multiple anodization steps.

A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure: ##STR00001##
wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, SO.sub.3H, PO.sub.3H, OH, NH.sub.2, and -halogen; wherein Y.sub.1 and Y.sub.2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, -alkylaminium, -alkynyl, PEGyl, PEGylcarboxylate, -PEGylaminium, -acyl-NH, -acyl-lysinyl-, -acyl-triazole, -PEGylcarboxyl-NH, -PEGylcarboxyl-lysinyl, and -PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH.sub.2, SH and OH; and R.sub.3 and R.sub.4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the imaging is a radio-isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and small molecule labeled with any of these isotopes, or wherein the imaging moiety is a chelator-complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-111, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227 and Gd-157.

The present disclosure provides a near-infrared fluorescent probe specifically targeting tumors as well as a synthesis method and use thereof. The near-infrared fluorescent probe specifically targeting tumors is a compound represented by formula I or a pharmaceutically available salt thereof: ##STR00001## wherein, X is a linker molecule selected from PEG.sub.n and glycine (G.sub.m), n=0-10, m=0-10, one end of the linker molecule is amino, and the other end of the linker molecule is carboxyl; Y is a dye molecule having a fluorescence excitation and emission spectrum within a near-infrared (NIR) range, and the compound represented by formula I or pharmaceutically available salt thereof can maintain or enhance the fluorescence of the dye molecule Y. The near-infrared fluorescent probe of the present disclosure can be rapidly cleared away in normal tissues, and remains for a long time in tumor sites, thereby taking the effect of living diagnosis. Hence, the near-infrared fluorescent probe of the present disclosure has a certain clinical application prospect, and can be applied to clinical surgery navigation.

An optical filter, including a first absorption layer containing a near-infrared absorbing dye and a transparent resin. The optical filter also includes a reflection layer. The first absorption layer has a thickness of 0.3 m to 10 m. The optical filter satisfies conditions described in the disclosure. An imaging apparatus including the optical filter.

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

There are provided a wavelength selective absorption filter including a resin, and four types of dyes A to D each having a main absorption wavelength range in different specific wavelength regions, in which an absorbance Ab () of the wavelength selective absorption filter at a wavelength nm satisfies specific Relational Expressions (I) to (VI), and an organic electroluminescent display device.

The present invention relates to the field of optical imaging. More particularly, it relates to fluorescent probes targeting carbonic anhydrase nine (CA-IX) comprising near-infrared (NIR) dyes of the cyanine. The invention also relates to the methods for preparing these compounds, to pharmaceutical compositions and kits incorporating them and to methods of use them as optical diagnostic agents in imaging or therapy of diseases such as solid tumors with hypoxic tissues involving cells expressing CA-IX. The compounds have formula (I).

##STR00001##

There are provided a wavelength selective absorption filter including a resin, and four types of dyes A to D each having a main absorption wavelength range in different specific wavelength regions, in which an absorbance Ab () of the wavelength selective absorption filter at a wavelength nm satisfies specific Relational Expressions (I) to (VI), and an organic electroluminescent display device.

Provided is a coloring composition containing a coloring agent compound represented by Formula 1 and a medium. ##STR00001## Description of T.sup.1, T.sup.2, R.sup.1, R.sup.2, X.sup.1, and n Formula 1 are omitted.